Post hoc analysis of ADAMANT, a phase 2 clinical trial of active tau immunotherapy with AADvac1 in patients with Alzheimer's disease, positive for plasma p-tau217. - Kovacech B; Cullen NC; Novak P; Hanes J; Kontsekova E; Katina S; Parrak V; Fresser M; Vanbrabant J; Feldman HH; Winblad B; Stoops E; et al. (Alzheimer's research & therapy, 2024)